Dihydropyrimidine dehydrogenase-related enzymes predict efficacy and adverse reactions of UFT+cisplatin neoadjuvant chemotherapy for gastric cancer

Anti-Cancer Drugs

Volumn 13, Issue 4, 2002, Pages 411-416

  Takiguchi, Nobuhiro ^a   Koda, Keiji ^a   Ooshima, Hirokazu ^a   Oda, Kenji ^a   Suzuki, Hirofumi ^a   Ishii, Rumiko ^a   Miyazaki, Masaru ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

5 Fluorouracil; Dihydropyrimidinase; Dihydropyrimidine dehydrogenase; Gastric cancer; UFT

Indexed keywords

CISPLATIN; DIHYDROPYRIMIDINASE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE; TEGAFUR; UFT;

ADJUVANT CHEMOTHERAPY; ANOREXIA; ARTICLE; CLINICAL ARTICLE; DIARRHEA; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; LEUKOPENIA; NAUSEA; PRIORITY JOURNAL; STOMACH CANCER; STOMATITIS; VOMITING;

AMIDOHYDROLASES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DIHYDROURACIL DEHYDROGENASE (NADP); GASTRECTOMY; HUMANS; OXIDOREDUCTASES; PREDICTIVE VALUE OF TESTS; STOMACH NEOPLASMS; TEGAFUR; URACIL;

EID: 0036241705     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200204000-00010     Document Type: Article

References (21)

1. Metabolism and mechanism of action of 5-fluorouracil
2. Clinical pharmacology of 5-fluorouracil
3. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile
4. Clinical implications of dihydropyrimidine dehydrogenase inhibition
5. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil
6. Clinical application of biochemical modulation in cancer chemotherapy: Biochemical modulating for 5-FU
7. Combined chemotherapy with 5-FU and low dose cisplatin for advanced or recurrent cancer of the digestive system and home anti-cancer chemotherapy
8. Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: A final report
9. Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography
10. Report on nationwide pooled data and cohort investigation in UFT phase II study
11. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
12. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo
13. Combination chemotherapy with tegafur-uracil (UFT) and cisplatin (CDDP) for advanced gastric cancer
14. Neoadjuvant chemotherapy with UFT for gastric cancer (second report)
15. Prediction of 5-fluorouracil sensibility by measurement of thymidylate synthase activity and dihydropyrimidine dehydrogenase activity against gastric cancer
16. Significance of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) activity in breast cancer tissue
17. Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumor tissues of colon and liver in humans
18. Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer
19. Screening for pyrimidine metabolism disorders using dried filter-paper urine samples: Method development and a pilot study in Nagoya City, Japan
20. Urinary screening for pyrimidine metabolism disorders. Reference ranges for dihydrouracil, uracil, and dihydrouracil/uracil ratio